Sales of smallpox vaccine halved last year at Acambis, the specialist biotechnology group, after the US government decided not to order extra stocks and despite wide-ranging preventative purchases.
Sales of smallpox vaccine halved last year at Acambis, the specialist biotechnology group, after the US government decided not to order extra stocks and despite wide-ranging preventative purchases.